<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Cancer Description</title>
</head>
<body>

  <h1>The Definition of Cancer</h1>

  <p>Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body. Cancer can start almost anywhere in the human body, which is made up of trillions of cells. Normally, human cells grow and multiply (through a process called cell division) to form new cells as the body needs them. When cells grow old or become damaged, they die, and new cells take their place.</p>

  <h2>How Does Cancer Develop?</h2>

  <h2>Types of Cancer</h2>

  <p>There are more than 100 types of cancer. Types of cancer are usually named for the organs or tissues where the cancers form. For example, lung cancer starts in the lung, and brain cancer starts in the brain. Cancers also may be described by the type of cell that formed them, such as an epithelial cell or a squamous cell.</p>

  <figure>
    <img src=https://www.cancer.gov/sites/g/files/xnrzdm211/files/styles/cgov_article/public/cgov_contextual_image/2019-06/1-how-does-cancer-form.jpg?h=b48714fe&itok=fc2eMUvr alt="Development Of Cancer"/>
    <figcaption>ENLARGE</figcaption>
  </figure>

  <p>Cancer is a genetic disease—that is, it is caused by changes to genes that control the way our cells function, especially how they grow and divide. Genetic changes that cause cancer can happen because of errors that occur as cells divide, damage to DNA caused by harmful substances in the environment, such as the chemicals in tobacco smoke and ultraviolet rays from the sun. (Our Cancer Causes and Prevention section has more information.) They can also be inherited from our parents.</p>

  <h2>Brain and Spinal Cord Tumors</h2>

  <p>There are different types of brain and spinal cord tumors. These tumors are named based on the type of cell in which they formed and where the tumor first formed in the central nervous system. For example, an astrocytic tumor begins in star-shaped brain cells called astrocytes, which help keep nerve cells healthy. Brain tumors can be benign (not cancerous) or cancerous. Cancerous tumors spread into, or invade, nearby tissues and can travel to distant places in the body to form new tumors (a process called metastasis). Cancerous tumors may also be called malignant tumors. Many cancers form solid tumors, but cancers of the blood, such as leukemias, generally do not.</p>

  <p>Benign tumors do not spread into, or invade, nearby tissues. When removed, benign tumors usually don’t grow back, whereas cancerous tumors sometimes do. Benign tumors can sometimes be quite large, however. Some can cause serious symptoms or be life-threatening, such as benign tumors in the brain.</p>

  <img src=data:image/jpeg;base64,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 alt="Development Of Cancer"/>

  <h2>Symptoms</h2>

  <p>Signs and symptoms caused by cancer will vary depending on what part of the body is affected. Some general signs and symptoms associated with, but not specific to, cancer, include:</p>
  <ul>
    <li>Fatigue: Lump or area of thickening that can be felt under the skin</li>
    <li>Weight changes, including unintended loss or gain</li>
    <li>Skin changes, such as yellowing, darkening or redness of the skin, sores that won't heal, or changes to existing moles</li>
    <li>Changes in bowel or bladder habits</li>
    <li>Persistent cough or trouble breathing</li>
    <li>Difficulty swallowing</li>
    <li>Hoarseness</li>
    <li>Persistent indigestion or discomfort after eating</li>
    <li>Persistent, unexplained muscle or joint pain</li>
    <li>Persistent, unexplained fevers or night sweats</li>
    <li>Unexplained bleeding or bruising</li>
  </ul>

  <h2>Treatment</h2>

  <p>There are basically 7 types of treatment for cancer:</p>
  <ul>
    <li>Surgery.</li>
    <li>Chemotherapy.</li>
    <li>Radiation Therapy.</li>
    <li>Targeted Therapy.</li>
    <li>Immunotherapy.</li>
    <li>Stem Cell or Bone Marrow Transplant.</li>
    <li>Hormone Therapy.</li>
  </ul>

  <p>According to new researches, new technology has been found for the treatment of cancer with the help of viruses.</p>

  <p>Scientists at the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust used a drug made from a genetically modified form of herpes simplex - the cold sore virus - to attack tumors in cancer patients' bodies, developing a cutting-edge form of cancer therapy in the process.</p>

  <h2>T-VEC Mechanisms of Action and Preclinical Activity</h2>

  <p>Oncolytic viruses include wild-type and modified live viruses and represent an innovative approach to cancer immunotherapy. In particular, T-VEC is a first-in-class oncolytic virus, intra-lesionally delivered, constituted by a genetically engineered herpes simplex virus type 1 (HSV-1) that selectively replicates in tumor tissue, lyses tumor cells, while promoting anti-tumor immunity [22]. Moreover, human GM-CSF gene is inserted in the virus and this results in local GM-CSF production, able to enhance the influx and activation of dendritic cells (DCs) needed to start a systemic antitumor response. Finally, the genes encoding neurovirulence factor ICP34.5 and ICP47 are functionally deleted in the viral drug [23,24]. Functional deletion of ICP34.5 attenuates viral pathogenicity and allows the virus to replicate selectively in tumors, while deletion of the ICP47 gene reduces virally mediated suppression of antigen presentation and increases the expression of the HSV US11 gene, which in turn, promotes virus growth in tumor cells without impairing tumor selectivity.</p>

  <p>In general, cancer immunotherapy relies on the recognition of tumor-associated antigens by immune cells and involves innate immunity components, as well as proinflammatory cytokines like tumor necrosis factor α and interferon-γ. When T-VEC immunotherapy is given intratumorally, it causes direct tumoral cells to die and acts as a source of antigens, favoring local recruitment of immune cells into the tumor microenvironment. Subsequently primed T cells induce a systemic polyclonal antitumor response, which can potentially address intra- and intertumoral heterogeneity In particular, T-VEC, entering the cancer cells through the herpes virus glycoproteins on the cell surface, favorably replicates and ultimately triggers cell lysis. In this way, tumor-derived antigens (TDA), GM-CSF and new viral particles are released allowing just one-time infection of surrounding tumoral cells and enhancing TDA spreading. In addition, danger-associated molecular pathways are activated, evoking a systemic antitumor effect and a complete immune response to occur.</p>

  <h2>Practically, T-VEC is administered through a series of intralesional injections and bypasses absorption barriers, so traditional pharmacokinetic studies were not relevant and therefore not performed. On mouse models, the highest concentration of viral DNA is detectable in the site of injection. However, viral DNA was also found at lower concentrations in non-target sites, like blood, spleen, lymph node, liver, heart, and kidney, while it was absent in the bone marrow, eyes, lachrymal glands, nasal mucosa, and feces. The attenuated virus is eliminated via host-defense mechanisms, including autophagy and adaptive immune responses, but viral DNA may persist in neuronal cell bodies surrounding the site of injection without clinical implications.</h2>

  <h2>Clinical Trials</h2>

  <p>T-VEC had been firstly tested in a Phase I study, where it demonstrated biological activity in terms of active viral replication, local reactions (erythema and inflammation of the injected lesions), granulocyte-macrophage colony-stimulating factor (GM-CSF) expression, tumor necrosis, and apoptosis, as evaluated in post-treatment biopsies.</p>

  <p>In phase 2, Shrinking in the tumor burden of injected and non-injected lesions, included visceral lesions, was reported, with most of the responses (92%) maintained for almost 3 years. However, the Phase III trial was hardly criticized because of the choice of a comparison arm which was not considered the correct standard of treatment, even though it was clearly designed in a period when new drugs and combinations were not approved yet.</p>

  <h2>Conclusion</h2>

  <p>The landscape of options for advanced melanoma is rapidly improving and progressing, with drugs and combinations able to significantly expand patients’ window of expectations. However, adverse events occurring during treatment can limit the dose intensity and duration of those treatments, thus consequently affecting their effectiveness.</p>

  <p>T-VEC is the first genetically modified herpes simplex virus-1-based oncolytic immunotherapy approved by FDA and EMA for the treatment of unresectable, cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. The positive effect of T-VEC, as a monotherapy or in combination with checkpoint inhibitors, which was observed in both injected and uninjected (including visceral) melanoma lesions, indicated that a systemic antitumor immune response was triggered. Trials are ongoing to confirm clinical results on larger numbers of patients and in comparison with the best standards of care, in order to confirm this approach is able to achieve high efficacy with low toxicity. Furthermore, new generation clinical trials incorporate regular sampling of both peripheral blood and tumor tissue, allowing basic and translational research, which will give insight on the mechanisms regulating tumor versus T-cells balance in the microenvironment and will characterize the immune response exploring its correlations with clinical outcomes.</p>

  <h2>Side Effects</h2>

  <ul>
    <li>Tiredness and Weakness: You might feel very tired and as though you lack energy. Various things can help you to reduce tiredness and cope with it, for example, exercise. Some research has shown that taking gentle exercise can give you more energy. It is important to balance exercise with resting.</li>
    <li>Flu-like Symptoms: About 9 out of 10 (about 90%) of people having T-VEC get flu-like symptoms. Symptoms include a high temperature, headaches, chills, muscle aches, shivering, and feeling tired and weak. These symptoms usually get better after 3 days.</li>
    <li>Feeling or Being Sick: Feeling or being sick is usually well controlled with anti-sickness medicines. It might help to avoid fatty or fried foods, eat small meals and snacks, and take regular sips of water. Relaxation techniques might also help. It is important to take anti-sickness medicines as prescribed even if you don’t feel sick. It is easier to prevent sickness rather than treat it once it has started.</li>
    <li>Injection Site: You might have a reaction to T-VEC at the injection site. This can make the area painful, red, bleed, swell, and may feel warm. It can also cause a discharge or leakage of fluid from the site.</li>
    <li>Headaches: Tell your healthcare team if you keep getting headaches. They can give you painkillers to help.</li>
    <li>Cough: Tell your doctor or nurse if you get a cough. It could be a sign of infection.</li>
    <li>Diarrhoea or Constipation: Tell your healthcare team if you have diarrhoea or constipation. They can give you medicine to help.</li>
    <li>Pain: T-VEC can cause pain in different parts of the body. It's common to feel pain in your muscles, joints, hands, feet, arms, or legs with T-VEC.</li>
  </ul>

  <p>How often do you have T-VEC? After the first injection of T-VEC, you go back 3 weeks later for the second. You then have injections every 2 weeks. You have T-VEC for at least 6 months. Your doctor may stop T-VEC if it’s no longer helping you or the side effects are too bad.</p>

</body>
</html>
